A 50-year-old woman with a long-standing history of rheumatoid arthritis (RA) presented with a persistent tongue ulcer after one year of treatment with intravenous abatacept (750 mg every four weeks) and leflunomide (20 mg daily). The lesion, located on the lateral border of the left side of the tongue, was biopsied and histopathologically diagnosed as moderately differentiated squamous-cell carcinoma (SCC). Given the temporal association with abatacept therapy and the absence of known risk factors for oral SCC, treatment with abatacept was discontinued immediately. The patient had no history of tobacco use at the time of diagnosis—though she had been an occasional smoker in her youth—and reported minimal alcohol consumption, limited to one glass of wine during meals on rare occasions. She had no personal or family history of head and neck cancers, although there was a familial predisposition to RA (a maternal cousin) and lung cancer (a first-degree cousin, aged 68).
The patient’s RA was diagnosed at age 33, characterized by symmetrical polyarthritis involving metacarpophalangeal, proximal interphalangeal, metatarsophalangeal, ankle, and left knee joints. Prior treatments included low-dose methylprednisolone, sulfasalazine, methotrexate (intramuscular), adalimumab, etanercept, and leflunomide. Therapy with adalimumab and etanercept was discontinued due to severe hypersensitivity reactions, including urticaria and respiratory distress. From April 2010 to August 2011, the patient received abatacept monthly in combination with leflunomide, achieving clinical remission. Abatacept was stopped in September 2011 following the diagnosis of SCC.
Surgical management included left partial glossectomy, left cervical lymphadenectomy, and reconstruction using a myomucosal flap from the buccinator muscle. Histopathological examination confirmed negative resection margins and no metastasis in regional lymph nodes, leading to a clinical staging of T1N0Mx.Antibody Dilution Buffer Autophagy Postoperative follow-up at six and ten months revealed no signs of recurrence based on physical examination, ultrasound, and computed tomography scans.CEACAM6 Antibody In stock
The case was reported to the Sardinian Regional Center of Pharmacovigilance and subsequently to the Italian Medicines Agency (AIFA) under report number 157854, as well as to the drug manufacturer.PMID:34962123 Causality assessment using the Naranjo algorithm yielded a score indicating a “probable” relationship between abatacept and the development of SCC. The WHO-UMC causality assessment system also supported this conclusion. While the Summary of Product Characteristics (SPC) for abatacept mentions risks of basal-cell carcinoma, skin papillomas, lymphoma, and malignant lung neoplasms, no prior cases of tongue SCC have been documented in association with abatacept use. Leflunomide was considered as a potential contributing factor; however, current evidence from large European registries does not link it to increased malignancy risk, particularly SCC.
This case represents the first documented instance of abatacept-associated squamous-cell carcinoma of the tongue. It underscores the importance of ongoing pharmacovigilance and long-term safety monitoring for biologic agents, especially in patients receiving prolonged therapy. Although single-case reports cannot establish causation, they provide critical signals for further investigation. Given the lack of comprehensive long-term data on abatacept’s oncogenic potential, clinicians should remain vigilant for unusual malignancies in patients on long-term immunomodulatory therapy. Future research must include robust observational studies and population-based registries to clarify the true incidence and risk profile of such adverse events.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com